All Press releases
All Primary and Secondary endpoints met in Nanexa’s Phase I study of the one-month GLP-1 depot NEX-22
22 November, 2024
Nanexa AB today announce positive results in the company’s Phase I study for NEX-22, long acting GLP-1, in type 2 diabetes. The study evaluates a once-monthly depot formulation of the GLP-1 analog liraglutide with Nanexa’s patented PharmaShell® system.
Nanexa publishes interim report for January-September 2024
7 November, 2024
Nanexas fas I-studie inom NEX-22 projektet för typ 2-diabetes har slutförts för samtliga patienter enligt plan.
Invitation to presentation of Nanexa’s Q3 report 2024
6 November, 2024
Nanexa AB (publ) will publish its report for the third quarter of 2024 on November 7, 2024 and invites to a comment of the report.
All patients have now completed their last visit in Nanexa’s Phase I trial of NEX-22 in Type 2 diabetes
5 November, 2024
Nanexa AB today announced that all patients have now completed the company’s Phase I study for NEX-22 in type 2 diabetes. The study evaluates a long-acting depot formulation of the GLP-1 analog liraglutide with Nanexa’s patented PharmaShell® system.
Comments on news about the license on a long-acting technology platform published this Monday
Ascendis Pharma, a prodrug technology platform company announced yesterday that they have signed a license agreement with Novo Nordisk. “Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases”. “A once-monthly GLP-1 receptor agonist will be the collaboration’s lead product candidate”.
Nanexa presented NEX-22 at PODD in Boston
31 October, 2024
Nanexa’s presentation of NEX-22 was received with great interest at the global conference PODD in Boston.
All patients in Nanexa Phase 1 study of NEX-22 dosed according to plan
1 October, 2024
Nanexa AB today announces that dosing of the last patient has been completed in the Phase 1 study of the long-acting depot formulation of the GLP-1 analog liraglutide PharmaShell®.
Nanexa starts the final dose group in the Phase 1 study of NEX-22 for treatment of Type 2 Diabetes
17 September, 2024
Nanexa AB today announces that the first patient in the third dose group with their long-acting depot formulation of the GLP-1 analog liraglutide has been dosed. The study started in Jun 2024 and have so far studied two consecutive dose groups with escalating doses.
Nanexa publishes interim report for January-June 2024
27 August, 2024
NEX-22 clinical trial initiated and proceeding with dose escalation as planned
Nanexa’s Phase I trial of NEX-22 in type 2- diabetes progresses with next dose group according to plan
1 August, 2024
Nanexa AB today announces that the company’s Phase 1 study for type 2 diabetes continues dose escalation according to plan with their long-acting depot formulation of the GLP-1 analog liraglutide.
Nanexa appoints new Chief Financial Officer
28 June, 2024
Nanexa AB (publ) today announces that Cecilia Danckwardt-Lillieström will take over as Chief Financial Officer as of September 1, 2024, as the current CFO Björn Svanström has chosen to leave the company.
First patient dosed in Nanexa’s Phase I trial of NEX-22 in type 2 diabetes
11 June, 2024
Nanexa AB today announces that the company’s Phase 1 study for type 2 diabetes has been initiated with dosing of the first patient. The study evaluates a long-acting depot formulation of the GLP-1 analog liraglutide with Nanexa’s patented PharmaShell® system within the NEX-22 project. The study is a dose-escalation study aimed at evaluating the pharmacokinetic profile, safety and tolerability of different doses.
Bulletin from Nanexa’s Annual General Meeting
15 May, 2024
The Annual General Meeting (AGM) of Nanexa AB (publ) has been held on May 15, 2024, at which meeting submitted proposals were passed. The complete proposals for resolutions are set out in the AGM notice.
Nanexa receives approval for NEX-22 clinical study
Nanexa AB today announces that the European Medicines Agency has approved the company’s clinical trial application for the Phase I study with NEX-22. NEX-22 is a long-acting depot formulation of the GLP-1 analogue liraglutide with Nanexa’s patented PharmaShell® system. The goal is to create a GLP-1 product that can be administered once a month in the treatment of Type 2 diabetes.
Nanexa publishes interim report for January-March 2024
3 May, 2024
NEX-22 clinical trial preparations ongoing and Novo Nordisk collaboration progressing well
Invitation to comment on Nanexa’s Q1 report 2024
30 April, 2024
Nanexa AB (publ) publishes on Friday, May 3, 2024, its interim report for the first quarter of 2024 and invites to a report commentary.
Nanexa invites to Capital Markets Day on May 7
29 April, 2024
Nanexa AB invites investors, analysts and other stakeholders to a Capital Markets Day on Tuesday, May 7, at 1:00-3:00 pm at the Royal Swedish Academy of Engineering Sciences (IVA) in Stockholm.
Approval of clinical trial application for NEX-22 study delayed
16 April, 2024
Nanexa AB today announces that in the ongoing review process of the clinical trial application for the phase I study with NEX-22, additional supplements have been requested from the German Medicines Agency, which in the new European regulatory process takes more time than expected.
Notice of annual general meeting in Nanexa AB (publ)
15 April, 2024
The shareholders in Nanexa AB (publ), reg.no 556833–0285 (the ”Company”) are hereby given notice that the annual general meeting will be held on Wednesday 15 May 2024, at. 3:00 pm, at Uppsala Business Park, Rapsgatan 7, Uppsala, Sweden.
Nanexa publishes annual report for 2023
27 March, 2024
Nanexa AB (publ) today announces that the annual report for 2023 has been published and is available on the company's website https://nanexa.com/en/financial-reports.
” A year that has brought us closer to commercialization and the expanding type 2 diabetes and obesity market.”
” In 2023,
Nanexa publishes year-end report and Q4 report 2023
21 February, 2024
NEX-22 clinical trial application submitted, secured funding and tactical priorities for 2024
Invitation to presentation of Nanexa’s year-end report and Q4 report 2023
20 February, 2024
Nanexa AB (publ) publishes tomorrow, February 21, 2024, its year-end report for the financial year 2023 and interim report for the fourth quarter of 2023 and invites to a report commentary.
Nanexa’s clinical trial application for NEX-22 Phase I study assessed by EMA
20 December, 2023
Nanexa AB today announces that the Clinical Trial Application for the Phase I study of NEX-22 in patients with type 2 diabetes has been received and validated by the European Medicines Agency (EMA).
Nanexa optimizes business operations through tactical priorities
Nanexa AB (publ) today announces that the Board has decided to focus the business on three key areas. The decision involves tactical priorities with the aim that today’s cash and expected revenues from evaluation agreements will be sufficient until the middle of 2025 and enable significant value-creating progress in prioritized collaborations and the own project NEX-22.
Nanexa changes Certified Adviser to Carnegie Investment Bank AB (publ)
30 November, 2023
Nanexa AB (publ) today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ).
Nanexa signs evaluation agreement with a large global pharmaceutical company
29 November, 2023
Nanexa AB (publ) today announced that the company has signed a Material Transfer and Feasibility Study Agreement with one of the largest global pharmaceutical companies for the evaluation of Nanexa’s drug delivery system, PharmaShell®, in a depot formulation of a monoclonal antibody.
Nanexa publishes interim report for January – September 2023
20 November, 2023
Positive clinical and preclinical results, and secured financing with focus on NEX-22 and next steps in partner projects
Nanexa presented Health Economical data at international conference
14 November, 2023
Nanexa AB today presented data from a health economical study at the international health economical conference ISPOR Europe 2023 in Copenhagen, Denmark. The presentation was selected for an oral podium presentation, given by Nanexa’s Medical Director, Bengt Gustavsson, and has the title “Association between Adherence to Lenalidomide and Patient-Reported Outcomes in Patients with Multiple Myeloma: A Systematic Literature Review”.
Nanexa announces outcome of rights issue
30 October, 2023
Today Nanexa AB (publ) (”Nanexa” or the “Company”) announces the outcome of the Company’s rights issue of approximately SEK 121m (the “Rights Issue”), for which the subscription period ended on 26 October 2023. The outcome of the Rights Issue shows that 42,146,268 shares, corresponding to approximately 34.7 percent of the Rights Issue, have been subscribed with and without the support of subscription rights. Hence, guarantee commitments of 32,853,732 shares, corresponding to approximately 27.1 percent of the offered shares, will be utilised. The Rights Issue will provide the Company with SEK 75m before deduction of transaction costs.
Nanexa receives additional subscription undertaking in the ongoing rights issue
20 October, 2023
Nanexa AB (publ) (”Nanexa” or the ”Company”) announced on 21 September 2023 that the board of the Company resolved to carry out an issue of shares with preferential rights for the Company’s existing shareholders (the “Rights Issue”). Nanexa hereby announces that the Company has received an additional subscription undertaking of approximately 4.7 MSEK from one of the Company’s largest shareholders, Applied Materials Europe B.V., an affiliate of Applied Ventures, LLC, in the ongoing Rights Issue.
Nanexa publishes EU growth prospectus in connection with rights issue
11 October, 2023
On September 21, 2023, the board of directors of Nanexa AB (publ) (”Nanexa” or the ”Company”), based on the authorisation granted by the annual general meeting on June 9, 2023, resolved on a rights issue of shares with preferential rights for the Company’s existing shareholders of approximately SEK 121 million (the “Rights Issue”). In connection with the Rights Issue, Nanexa has prepared an EU growth prospectus which today has been approved by the Swedish Financial Supervisory Authority and published on the Company’s website www.nanexa.com.
Nanexa reports preliminary key financial information for the period January-September 2023
As communicated in a press release on September 21, 2023, the Board of Directors of Nanexa AB decided, as a result of the announced rights issue, to change the date of the interim report for the period January-September 2023 to November 20, 2023. With this press release, preliminary financial key information for the current period is reported.
Nanexa completes clinical phase I study with NEX-20
5 October, 2023
Nanexa AB today announces that the phase I study NEX-20-01 has been completed with the last follow-up visits for the last of the three dose levels studied. Nanexa has previously communicated positive results from the pharmacokinetic evaluation and has now also completed the collection of safety and tolerability data that also supports the further development of the project.
Nanexa invites to investor meeting on October 9th in Uppsala
28 September, 2023
Nanexa AB invites investors and analysts to the company’s premises at Uppsala Business Park on Monday, October 9th, from 10:00 AM to 13:00 PM. Chairman Göran Ando, CEO David Westberg and others from the management team will present the company, the rationale and objectives for the announced rights issue, and future plans.
Invitation to commentary regarding rights issue
22 September, 2023
Nanexa AB (publ) invites to a live commentary on the announced rights issue.
Nanexa carries out a rights issue of approximately SEK 121 million
21 September, 2023
Nanexa AB (publ) (”Nanexa” or the ”Company”) carries out an issue of shares of approximately SEK 121 million before transaction costs with preferential rights for the Company’s existing shareholders (the “Rights Issue”). The board of directors resolved today, on September 21, 2023, on the Rights Issue on the basis of the authorisation from the annual general meeting on June 9, 2023. The Company has received subscription undertakings and guarantee commitments in a total amount of SEK 75 million, which corresponds to approximately 62 per cent of the Rights Issue. The purpose of the Rights Issue is to strengthen the Company’s financial position, to enable the planned clinical studies as well as carry out other value creating activities supporting PharmaShell and the NEX projects. As a consequence of the Rights Issue, the board of directors has resolved to delay the publication of the Company’s interim report for the period January – September 2023 until November 30, 2023.
Nanexa presents at ISPOR Europe 2023
6 September, 2023
Nanexa AB today announced that its scientific abstract has been accepted for the international health economic conference ISPOR Europe 2023, November 12-15, in Copenhagen, Denmark. The abstract is entitled “Association between Adherence to Lenalidomide and Patient-Reported Outcomes in Patients with Multiple Myeloma: A Systematic Literature Search” and has been accepted as an oral podium presentation.
Nanexa is granted patent in India
30 August, 2023
Nanexa AB (publ) today announced that the company has been granted a patent in India relating to its PharmaShell® technology. This patent covers the relevant manufacturing method, coated drug particles that result therefrom, and pharmaceutical composition containing those particles.
Nanexa publishes interim report for January – June 2023
23 August, 2023
Strong preclinical progress with NEX-22, positive Phase 1 data with NEX-20 and several partner projects in preclinical evaluation
Invitation to presentation of Nanexa’s Q2 report 2023
22 August, 2023
Nanexa AB (publ) will publish its report for the second quarter of 2023 tomorrow August 23, 2023 and invites to a comment of the report.
Nanexa confirms continued positive results from a new preclinical study of NEX-22
Nanexa AB today announced that a preclinical study of NEX-22 in minipigs confirms a long release profile of liraglutide, which was previously seen in rats. The data show that a release profile of NEX-22 can be obtained for at least 28 days, which was the duration of the pharmacokinetic study and the goal of the study.
Nanexa obtains pharmacokinetic data from the NEX-20 Phase 1 study confirming controlled release of lenalidomide
Nanexa AB today announced that pharmacokinetic data from the Phase 1 study NEX-20-01 confirmed a release profile of lenalidomide in different doses up to 21 days.
Summer letter from Nanexa
10 July, 2023
The second quarter of 2023 has come to its end and many of us in Sweden go into the holiday season. We at Nanexa can summarize the first half of 2023 as being very productive with both our own projects and our partner projects. Also, we have had the chance to meet new potential partners at different conferences in EU and US where we can see that the interest for our drug delivery system PharmaShell is increasing as we are able to present more and more data describing the unique features of the system. One clear reflection from these conferences is that our ability to work with and improve formulations of biologics such as peptides and monoclonal antibodies generates great interest among many of the big pharma companies.
Bulletin from Nanexa’s Annual General Meeting 2023
9 June, 2023
The Annual General Meeting (AGM) of Nanexa AB (publ) has been held on June 9, 2023, at which meeting submitted proposals were passed. The complete proposals for resolutions are set out in the AGM notice.
Nanexa has completed the planned recruitment to the Phase 1 study of NEX-20
Nanexa AB today announced that the recruitment and dosing has been completed in the NEX-20 Phase 1 study. Since December last year, healthy volunteers have been administered single doses in three sequential escalating dose groups. Data on the pharmacokinetic profile, safety and tolerability is now being collected for the last dose group, and results are expected to be presented after the summer.
Nanexa signs contract with leading international diabetes CRO for Phase I study with NEX-22
1 June, 2023
Nanexa AB today announced that the company is engaging the contract research organization (CRO) Profil, in Neuss, Germany, ahead of the upcoming start of a phase I study with NEX-22, a monthly depot of liraglutide for the treatment of type 2 diabetes and ultimately obesity. Profil is highly specialized in early clinical studies in diabetes and obesity, and has an excellent global reputation for conducting clinical research in these two indications.
Notice of Annual General Meeting in Nanexa AB
10 May, 2023
The shareholders in Nanexa AB (publ) reg. no. 556833–0285 (the “Company”) are hereby given notice that the annual general meeting will be held on Friday 9 June 2023, at 10:00am at Uppsala Business Park, Rapsgatan 7, Uppsala, Sweden.
Nanexa publishes interim report for January – March 2023
4 May, 2023
Positive pre-clinical data with NEX-22, NEX-20 phase I continues and good progress in partner projects
Nanexa publishes annual report for 2022
3 May, 2023
Nanexa AB (publ) today announced that the annual report for 2022 has been published and is available on the company's website https://nanexa.com/en/financial-reports/.
”2022 was a year in which we took large steps towards commercialisation of our PharmaShell system.
NEX-22 preclinical data shows controlled release of liraglutide for one month
23 March, 2023
Nanexa AB (publ) today announced positive outcome in the first preclinical study with NEX-22. In a one-month study in rats, single doses of two different PharmaShell® formulations were studied in different doses. The results show a controlled release of liraglutide, with plasma exposure over 28 days for NEX-22, compared to around 2 days for a formulation with liraglutide without the PharmaShell coating.
Nanexa publishes year-end report for 2022
16 February, 2023
Agreement and directed issue to Novo Nordisk, solution to patent infringement lawsuit and phase 1 study with NEX-20 started
Invitation to presentation of Nanexa’s year-end report and Q4-report
15 February, 2023
Nanexa AB (publ) will tomorrow, the 16th of February, 2023, publish its year-end report for the fiscal year 2022 and interim report for the fourth quarter of 2022, and invites to a comment of the report.
Nanexa participates at the 4th annual “Beyond Medicines’ Barriers Meeting”, arranged by the International Myeloma Foundation
8 February, 2023
On February 7-8, Nanexa participates in Lugano, Switzerland, as one of the sponsors at the 4th annual ”Beyond Medicines’ Barriers Meeting”, arranged by the International Myeloma Foundation (IMF).
Invitation to commentary regarding Nanexa’s press release on 21 December 2022
21 December, 2022
Nanexa AB (publ) comments, on the 22 of December 2022, on the occasion of the press release on 21 December 2022, and invites to a live commentary.
Nanexa signs an exclusivity and evaluation agreement worth SEK 46.1 million and completes a directed share issue of SEK 17.2 million to Novo Nordisk
Nanexa AB (publ) (“Nanexa” or the “Company”) today announces that the Company has signed a Material Transfer and Feasibility Study Agreement (the “Evaluation Agreement”) with leading global pharmaceutical company Novo Nordisk A/S (”Novo Nordisk”) for the evaluation of Nanexa’s drug delivery system PharmaShell® with Novo Nordisk products. As part of the Evaluation Agreement, Nanexa will receive payments of approximately SEK 46.1 million for providing Novo Nordisk exclusivity and performing work under the Evaluation Agreement, whereof approximately SEK 41.7 million is an upfront payment at signing. In connection with the signing of the Evaluation Agreement, the board of directors of Nanexa also resolved, based on the authorisation granted by the annual general meeting held on 9 June 2022, to carry out a directed share issue to Novo Nordisk of 10,000,000 shares at a subscription price of SEK 1.72 per share (the “Directed Share Issue”) through which Nanexa raises gross proceeds of approximately SEK 17.2 million. The subscription price is equivalent to a premium of 33 percent versus the closing price yesterday for the Company’s shares. In total, Nanexa will thus receive approximately SEK 63.3 million from the Evaluation Agreement and the Directed Share Issue.
Nanexa has started the Phase 1 study of NEX-20 according to plan
6 December, 2022
Nanexa AB (publ) today announced that the first dose of NEX-20 has been administrated in the Phase 1 study NEX-20-01.
Nanexa AB and VitriVax, Inc. have resolved the patent infringement lawsuit
16 November, 2022
Nanexa AB and VitriVax, Inc. jointly announce that they have resolved the patent infringement lawsuit filed by Nanexa AB against VitriVax, Inc. in the United States District Court for the District of Delaware.
Nanexa receives approval to start clinical trial with NEX-20
14 November, 2022
Nanexa AB (publ) today announced that it has received approval from the Swedish Medical Products Agency to initiate a clinical trial of its drug candidate NEX-20, a long-acting formulation of lenalidomide, based on the PharmaShell® system, intended for the maintenance treatment of multiple myeloma cancer.
Nomination Committee for Nanexa AB (publ) Annual General Meeting 2023
10 November, 2022
The Nomination Committee has been appointed in Nanexa AB (publ) for the Annual General Meeting 2023 in accordance with the principles adopted by Nanexa’s Annual General Meeting on 9 June 2022.
Nanexa publishes interim report for January – September 2022
25 October, 2022
Launch of NEX-22 in type 2 diabetes and new partner projects with great potential
Nanexa signs evaluation agreement with a Speciality Pharma company
21 October, 2022
Nanexa AB (publ) today announced that the company has signed a Material Transfer and Feasibility Study Agreement with a Speciality Pharma company, for evaluation of the PharmaShell® drug delivery system making a depot formulation of specific compounds for intravitreal delivery.
Nanexa AB and Vitrivax, Inc reach agreement in principle
27 September, 2022
Today Nanexa AB and VitriVax, Inc. filed a notice with the Court requesting that Nanexa’s patent infringement lawsuit pending in the District of Delaware be stayed while the parties work to finalize settlement terms to which they have agreed in principle.
Nanexa launches NEX-22 product project to address a huge market
15 September, 2022
Nanexa AB (publ) announced today that it has decided to develop a long-acting formulation of liraglutide with PharmaShell® for the treatment of type 2 diabetes. NEX-22 will be the company’s third proprietary product development project.
Nanexa signs evaluation agreement with a Global Pharmaceutical Company
30 August, 2022
Nanexa AB (publ) today announce that the company has signed a Material Transfer and Feasibility Study Agreement with an option to license, with a Global Pharmaceutical Company, for evaluation of the PharmaShell® drug delivery system making a depot formulation of a specific compound.
Nanexa publishes interim report for January – June 2022
26 August, 2022
The pilot plant inaugurated and GMP certified, patent approved in Europe and product projects approaching clinical phase
Nanexa receives extended GMP-certificate for the new pilot plant
25 August, 2022
Nanexa AB (publ) today announced that the company’s new pilot plant in Uppsala has received certification from the Swedish Medical Products Agency for production of clinical trial material.
Nanexa extends collaboration agreement with Applied Materials
21 July, 2022
Nanexa AB (publ) today announced that the company has expanded its collaboration agreement with Applied Materials, Inc., through an amendment regulating commercial arrangements, paving the way for potential future license agreements with customers in the pharmaceutical industry.
Bulletin from Nanexa’s Annual General Meeting 2022
9 June, 2022
The Annual General Meeting (AGM) of Nanexa AB (publ) has been held on June 9, 2022, at which meeting submitted proposals were passed. The complete proposals for resolutions are set out in the AGM notice.
Nanexa receives grant from VINNOVA for study with monoclonal antibodies
24 May, 2022
Nanexa AB today announced that the company has been granted funding under the VINNOVA project “Verification in Test Center, Part III” for a maximum amount of SEK 290,000. The funds will be used for an internal research project at Nanexa with the aim of coating monoclonal antibodies (mAbs) with PharmaShell®.
The European Patent Office has granted Nanexa’s PharmaShell® patent
28 April, 2022
Nanexa AB (publ) today announced that the European Patent Office (EPO) has granted the company’s patent application relating to the drug delivery system PharmaShell®. The patent protection covers the manufacturing method of PharmaShell and products produced using the method.
Nanexa publishes interim report for January – March 2022
20 April, 2022
Positive development in the product projects and in the patent portfolio
Positive development in Nanexa’s patent litigation case
17 March, 2022
Nanexa AB today announced that the United States District Court for the District of Delaware in Nanexa AB v. VitriVax, Inc. C.A. No. 21-764 (JLH), today denied VitriVax’s motion to dismiss Nanexa’s complaint for patent infringement and denied as moot VitriVax’s motion to stay discovery. Furthermore, Nanexa’s motion to compel discovery was granted. Nanexa will continue to actively protect its valuable intellectual property rights related to its drug delivery system PharmaShell®.
Nanexa CEO invited as speaker at CRS 2022 Annual Meeting
8 March, 2022
Nanexa AB today announced that CEO David Westberg has been invited as speaker and the company also got three abstracts approved for publication as posters at CRS 2022 Annual Meeting and Expo, on July 11-15, 2022, in Montreal, Canada.
Nanexa publishes year-end report for 2021
17 February, 2022
Additional evaluation agreement and positive results in preclinical investigation of NEX-18
Nanexa takes next step in development of NEX-18
10 February, 2022
Nanexa AB (publ) today announces that the company’s preclinical investigation indicates the cause and a potential solution to the moderate skin reactions that arose in the clinical study with NEX-18. With these results, Nanexa is expanding its preclinical program to optimize the formulation of NEX-18. The project is expected to re-enter clinical phase next year.
Nanexa granted patent in the USA
14 January, 2022
Nanexa AB (publ) today announced that the company has received a new patent in the USA. The newly issued patent (US 11,214,865 B2) relates to an ALD reactor adapted for large scale production of PharmaShell® coated drugs.
Nanexa publishes interim report for January – September 2021
10 November, 2021
Substantial orders and pause in the NEX-18 study
Nanexa initiates complementary preclinical studies
25 October, 2021
Nanexa AB today announces that the company has initiated complementary preclinical studies to investigate what caused the moderate skin reactions that occurred in the company’s phase I study with NEX-18, a depot formulation of 5-azacitidine.
Nanexa signs additional evaluation agreement
13 October, 2021
Nanexa AB today announced that the company has signed an additional so-called Material Transfer and Feasibility Study Agreement with one of the company’s existing customers, for evaluation of the PharmaShell® technology with a specific biological drug substance.
Nanexa receives decision on sanction fee from Finansinspektionen regarding case from 2017
5 October, 2021
Nanexa AB today announces that the company has received a decision from Finansinspektionen (Sweden’s financial supervisory authority) to pay a penalty fee of SEK 1,000,000 regarding events that occurred in 2017.
Nanexa pauses NEX-18 study
24 September, 2021
Nanexa today announces that the inclusion of patients in the company’s phase I study with NEX-18, a depot formulation of 5-azacitidine, is paused due to moderate skin reactions at the injection site.
Nanexa receives orders for coating of sensors
3 September, 2021
Nanexa AB (publ) today announced that the company has received two orders for a substantial number of sensors for detection of radioactive isotopes of the noble gas xenon, from two American customers, totaling approximately SEK 1.7 million.
Nanexa publishes interim report for January – June 2021
20 August, 2021
First clinical study started and long-term financing secured
EPO communicates intention to grant Nanexa’s PharmaShell® patent in Europe
7 July, 2021
Nanexa AB is pleased to announce that the European Patent Office (EPO) has today issued a communication advising that it intends to grant a European patent relating to Nanexa’s PharmaShell® technology.
Nanexa raises approximately SEK 126.7 million in fully subscribed rights issue
Nanexa AB (publ) (”Nanexa” or the “Company”) today announces that the new share issue with preferential rights for the Company’s existing shareholders of approximately SEK 126.7 million before transaction costs (the “Rights Issue”) was fully subscribed. Approximately 16.6 percent of the Rights Issue was subscribed for through subscription commitments. In addition to the subscription through subscription commitments, approximately 40.2 percent was subscribed for by the use of subscription rights, and approximately 14.9 percent was subscribed for without subscription rights. The remaining part of the Rights Issue was subscribed for through guarantee commitments from the existing shareholder Rutger Arnhult via M2 Capital Management, and from external investors, including, amongst others, Health Runner and Modelio Equity.
Nanexa granted patent in South Korea
22 June, 2021
Nanexa AB (publ) today announced that the company has been granted a patent in South Korea relating to PharmaShell®-coated drugs.
Nanexa invites to webcast
14 June, 2021
Nanexa invites to a webcast where CEO David Westberg, Chairman of the Board Göran Ando and CFO Björn Svanström will provide an update of Nanexa and the purpose of the company’s upcoming rights issue.
Nanexa publishes EU growth prospectus in connection with fully guaranteed rights issue
11 June, 2021
On 7 June 2021, the board of directors of Nanexa AB (publ) (”Nanexa” or the ”Company”), based on the authorisation granted by the annual general meeting on 24 May 2021, resolved on a rights issue of shares with preferential rights for the Company’s existing shareholders of approximately SEK 126.7 million (the “Rights Issue”). In connection with the Rights Issue, Nanexa has prepared an EU growth prospectus which today has been approved by the Swedish Financial Supervisory Authority and published on the Company’s website www.nanexa.com.
The board of directors of Nanexa has resolved on a fully guaranteed rights issue of approximately SEK 126.7 million
7 June, 2021
The board of directors of Nanexa AB (publ) (”Nanexa” or the ”Company”) has today, based on the authorisation granted by the annual general meeting on 24 May 2021, resolved on a rights issue of shares with preferential rights for the Company’s existing shareholders of approximately SEK 126.7 million (the “Rights Issue”). The Rights Issue is fully covered by subscription undertakings and guarantee commitments. Certain existing shareholders have entered into subscription commitments, amongst others Rutger Arnhult via M2 Capital Management, Jan Petersen, Applied Ventures, and members of the Company’s board of directors and management team, including amongst others CEO David Westberg and chairman of the board Göran Ando. Furthermore, guarantee commitments have been provided by the existing shareholder Rutger Arnhult via M2 Capital Management, and external investors, including amongst others Health Runner and Modelio Equity. In addition, the board of directors may, based on the authorisation granted by the annual general meeting on 24 May 2021, resolve on an over-allotment issue of up to approximately SEK 23.5 million (the “Over-allotment Issue”), conditional upon the Rights Issue being oversubscribed. The purpose of the Rights Issue and the Over-allotment Issue (together the ”New Issues”) is to strengthen the Company’s financial position and to enable the planned clinical studies as well as other value creating activities supporting PharmaShell and the NEX projects.
Nanexa includes first patient in PharmaShell study
31 May, 2021
Nanexa AB (publ) today announces that the company has included the first patient in its first clinical study with PharmaShell®. A phase I study in Nanexa’s product project NEX-18.
Nanexa filing complaint of patent infringement
Nanexa AB (publ) today announces that the company has filed a complaint of patent infringement against the American company VitriVax Inc.
Bulletin from the Annual General Meeting of Nanexa
24 May, 2021
On May 24, 2021, the Annual General Meeting of Nanexa AB (publ) was held. Due to the risk of spreading of Covid-19 and the authorities’ regulations and advice, the Annual General Meeting was held only through advance voting (so-called postal voting) in accordance with temporary rules.
Nanexa granted patent in China
19 May, 2021
Nanexa AB (publ) today announced that the company has been granted a patent in China. This primary patent covers the manufacturing method, products that come out of it, and the use of PharmaShell®-coated drugs.
Interim report Q1 2021
6 May, 2021
“The development of Nanexa is continuing and at the beginning of the quarter we started our second proprietary product project, NEX-20. The choice of multiple myeloma as our second indication fits well with myelodysplastic syndrome (MDS) in NEX-18 and creates an interesting portfolio in haematological cancer. In 2021, we intend to identify another project, NEX-21, where PharmaShell® can create another unique product with major potential.” David Westberg, CEO Nanexa AB.
Nanexa launches clinical trial for NEX-18
28 April, 2021
Nanexa AB (publ) today announces that the company has started its first clinical study with PharmaShell®, a phase I study in Nanexa’s product project NEX-18, at the Karolinska University Hospital.
Nanexa announces second investment from Applied Ventures
15 April, 2021
On December 17, 2020, Nanexa AB (publ) (“Nanexa” or “the Company”) announced that the Company has entered into an investment agreement with Applied Ventures, LLC (“Applied Ventures”), the venture capital arm of Applied Materials, Inc., through which Applied Ventures intends to invest up to USD 3 million in Nanexa during 2021 to support Nanexa’s continued development and expansion. On January 12, 2021 Nanexa issued 686,492 shares, corresponding to an investment amount of USD 1m, and 3,558,278 warrants of the 2020/2021 series (the “Warrants”) to Applied Ventures. The Warrants carry the right, but not the obligation, for Applied Ventures to subscribe for up to 3,558,278 shares in Nanexa during two exercise periods, April 1-15, 2021 and December 1-15, 2021. Applied Ventures decides the number of Warrants to be exercised during each subscription period. The subscription price shall be equal to volume-weighted average price during the ten trading days immediately before the respective subscription period, less ten percent. In the first subscription period under the investment agreement, April 1-15, 2021, Applied Ventures has subscribed to 480,879 shares at SEK 8,95 per share, equaling SEK 4.3 million or around USD 0.5 million.
The covid situation at Uppsala University Hospital affects the start of the NEX-18 phase Ia study
12 April, 2021
Nanexa’s planned phase Ia study in the NEX-18 project was set to start on April 15. The clinic at Uppsala University hospital informed Nanexa last Friday that their staff need to be used in other departments for covid care, and therefore, the study can not be started as planned on the 15th. The company is in close contact with the clinic to find the quickest solution possible. On Nanexa’s other study site, at the Karolinska University Hospital in Huddinge, preparations are ongoing and the study is expected to start according to plan by end of April.
Nanexa recruits head of pharmaceutical development
15 March, 2021
Nanexa today announces that the company has recruited Jonas Fransson as head of pharmaceutical development as part of a strengthening of the organization. Jonas Fransson has long and solid experience in drug development and will start on May 1 this year and will be part of Nanexa’s management team.
Nanexa Year-end report 2020
18 February, 2021
“The fourth quarter of 2020 was one of the most eventful in Nanexa’s history. We received a GMP certificate for drug manufacturing and a clinical trial permit for our NEX-18 project. We signed a collaboration agreement with Applied Materials and an investment agreement with Applied Ventures and, after careful evaluation, we decided shortly after the end of the quarter to choose lenalidomide for our NEX-20 project.” David Westberg, CEO Nanexa
Nanexa announces the result of the use of warrants of series TO2
Nanexa AB (”Nanexa” or ”the Company”) today announced the result of the use of warrants of series TO2, which were issued in connection with the Company’s rights issue in February 2020. The result shows that a total of 2,956,588 warrants were used to subscribe for 2,956,588 new shares in the Company, corresponding to approximately 97.5 percent of the total number of issued warrants of series TO2.
Nanexa update 2021 – webcast
2 February, 2021
Nanexa invites to a webcast hosted by CEO David Westberg, Chairman Göran Ando, and board member Bengt Gustavsson, who will give an update and talk about their view on Nanexa and the current project portfolio.
Nanexa signs agreement with a European Biotech company for evaluation of PharmaShell®
28 January, 2021
Nanexa AB (publ) today announced that the company has signed an evaluation agreement, a so-called Material Transfer and Feasibility Study Agreement, with a non-disclosed European biotech company. The company is running a development project within the cardiovascular field, where PharmaShell®, as the drug delivery system, can enable an injectable product that releases the drug substance during 1-2 weeks.
Nanexa receives “Notice of Allowance” for patent application in Canada
26 January, 2021
Nanexa AB (publ) today announced that the company has received a so-called “Notice of Allowance” for a patent application in Canada. The patent application refers to PharmaShell® administered in every conceivable way, for example by parenteral injection, inhalation or by oral administration.
Nanexa chooses lenalidomide for the project NEX-20
13 January, 2021
Nanexa AB today announces that the company has chosen to develop a long-acting formulation of lenalidomide for the treatment of multiple myeloma. NEX-20 will be the company’s second own product project.
Nanexa completes the first part of the directed share issue to Applied Ventures
12 January, 2021
On December 17, 2020, Nanexa AB (publ) (“Nanexa” or “the Company”) announced that the Company has entered into an investment agreement with Applied Ventures, LLC (“Applied Ventures”) through which Applied Ventures intends to invest up to USD 3 million in Nanexa during 2021 to support continued development and expansion. Today, January 12, 2021, Nanexa’s Board of Directors has decided, with the support of the authorization received at the Annual General Meeting on June 2, 2020, to issue 686,492 shares and 3,558,278 warrants (the “Directed Issue”) to Applied Ventures. In accordance with the investment agreement, the subscription price for the shares in the Directed Issue has been set at the volume-weighted average price (“VWAP”) during the period December 22, 2020 through January 11, 2021 with a deduction of five percent, corresponding to SEK 11.99 per share.
Nanexa enters into an investment agreement with Applied Ventures of USD 3 million
17 December, 2020
Nanexa AB (publ) today announced that the company has entered into an investment agreement with Applied Ventures, LLC, the venture capital arm of Applied Materials, Inc., whereby Applied Ventures intends to invest up to USD 3 million in Nanexa during 2021 to support continued development and expansion. USD 1 million will be invested in January 2021 and additional investments of up to USD 2 million are planned later in 2021. The investment will be made through a directed issue to Applied Ventures of a mix of shares and share warrants decided upon by Nanexa with support of the authorization of the Annual General Meeting held on June 2, 2020 (the “Directed Issue”).
Nanexa signs Collaboration Agreement with Applied Materials, Inc.
Nanexa AB (publ) today announced that the company has entered into a collaboration agreement with the leading materials engineering solutions company Applied Materials, Inc. in order to establish a scaled-up GMP production site for ALD-coated pharmaceuticals located at Nanexa’s facilities in Uppsala.
Nanexa receives clinical trial approval for NEX-18
10 December, 2020
Nanexa AB (publ) today announced that the company has received permission to start the clinical trial for the drug candidate NEX-18 by the Swedish Medical Products Agency, Läkemedelsverket.
Nanexa in late stage partnering and investment negotiations with Applied Materials and Applied Ventures
27 November, 2020
Nanexa AB (publ) today announces that the company is in late stage negotiations about entering into a joint development agreement with the world leading materials engineering solutions company Applied Materials Inc.
Market Notice 76/20 – Information regarding Nanexa AB”s subscription options
24 March, 2020
The trading in Nanexa AB''s subscription options NANEXA TO2 will take place from April 1, 2020.
Please see the company''s webpage for the full terms of the subscription option.
Market Notice 74/20 – Last day of trading in Nanexa AB”s BTU
23 March, 2020
Last day of trading in the company''s paid subscribed unit, NANEXA BTU, is March 26, 2020.?
Information about the paid subscribed unit:
Shortname: NANEXA BTU
ISIN: SE0013774619
Orderbook-ID: 5U4E
CFI: MCMUXR
FISN: NANEXA/UT 4 AK + 2 TO
Last day of trading: March 26,
Market Notice 28/20 – Information regarding the rights issue from Nanexa AB
3 February, 2020
The last day of trading in the company"s shares NANEXA including the right to receive unit rights is February 5, 2020. The first day excluding the right to obtain the rights is February 6,
Marknadsmeddelande 23/19 – Sista dag för handel med teckningsoption i Nanexa AB
23 January, 2019
Sista dag för handel med bolagets teckningsoption serie TO 1, är den 30 januari 2019.
